Patrick Vallance

@article{Vallance2010PatrickV,
  title={Patrick Vallance},
  author={Patrick Vallance},
  journal={Nature Reviews Drug Discovery},
  year={2010},
  volume={9},
  pages={834-834}
}
  • P. Vallance
  • Published 29 October 2010
  • Medicine
  • Nature Reviews Drug Discovery
In your view, what are the main challenges of developing drugs for rare diseases and, now that GSK has a dedicated unit specializing in this area, how can the company help to address them? Approximately 7,000 rare diseases have been identified worldwide. But, if you look across at all of the major pharmaceutical companies, we have medicines for only 80–90. So, there is a massive unmet need that we aim to help address. Also, for some rare diseases — particularly those of genetic origin — you… 
4 Citations
Integrating internal and external bioanalytical support to deliver a diversified pharmaceutical portfolio.
TLDR
This journey has involved asking where the authors believe an internal bioanalytical facility offers the greatest benefit to progressing drug candidates through the drug-development cycle and where externalization can help free up internal resources, adding flexibility to the organization in order to deal with the inevitable peaks and troughs in workload.
Network and Systems Medicine: Position Paper of the European Collaboration on Science and Technology Action on Open Multiscale Systems Medicine
TLDR
The development of multi-omic approaches as well as new digital tools provides a unique opportunity to explore complex biological systems and networks at different scales and the health care system will also have to evolve, if not revolutionize, in terms of organization and management.